Global Nanoemulsion Market Size (2024 - 2029)

Nanoemulsion Market Analysis

The nanoemulsion market is expected to register a CAGR of nearly 7.2% during the forecast period (2022-2027).

The COVID-19 outbreak is expected to have a positive effect on the market for nanoemulsions. Nanoemulsions are used extensively as vaccine carriers and adjuvants. In vaccine development, nanoemulsions are used as they offer various advantages like increasing the surface area of an antigen allowing for favorable antigen presentation, slow release of the antigen, and uniform dispersion, and good stability of the vaccine. In a research article appearing in the September 2020 issue of News-Medical.Net, researchers stated that a potential COVID-19 vaccine can include a cationic nanoemulsion-based system. These nanoemulsion systems can produce immune responses that are similar to live attenuated vaccines but do not run the risk of reversion. moreover, as per a research article 'Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases' published in May 2022, revealed that nanoemulsions and their modified forms have been successfully employed for the delivery of antimicrobials to treat infectious disease. These nanoemulsion-based formulation systems are shifting the paradigm for therapeutics and diagnosis of infectious diseases. These developments are likely to affect the market in a positive manner.

The studied market growth can largely be attributed to factors such as the increasing burden of chronic diseases and development of vaccines, rising adoption of targeted therapeutics and image-guided therapies, and the high stability and chemical properties for efficient drug delivery.

Vaccines play a significant role in the treatment of several chronic and infectious diseases, which gained more prevalence in recent decades. An increasing number of biopharmaceutical companies are using nanoemulsion formulations in the development of vaccines. Moreover, companies, such as BlueWillow Biologics Inc., a nanotechnology-based vaccine manufacturer, received a United States patent for an intranasal NanoVax anthrax vaccine. The NanoVax nanoemulsion platform could elicit both a systemic and mucosal response when administered intranasally. This was in contrast with other conventional vaccines are injected (intramuscular) and fail to provide mucosal immunity. The NanoVax platform has also been used to develop vaccines against two strains of genital herpes viruses, HSV1 and HSV2.

The last decade showed several promises, with successful results of nanoemulsion being used as adjuvants for vaccines to treat chronic infections and cancer diseases through targeted therapies. Increasing research projects through institutes, in collaboration with various government funds and companies, are being witnessed, which primarily deal with the improvement of the oral delivery of drugs for the management of chronic diseases. Nanoemulsion provides enhanced transdermal permeation of drugs, which increases the plasma concentration profiles and bioavailability of the drug. In the case of cancer indications, the nanoemulsion and nanoparticle form offers a higher potential of killing the cancer cells, as well as better treatment of cancer, osteoarthritis, and fibromyalgia, among others. With the constant demand for new and improved vaccines, nanoemulsion applications are expected to increase globally and drive the market.

Nanoemulsion Industry Segmentation

Nanoemulsions are nano-sized emulsions, which are manufactured for improving the delivery of active pharmaceutical ingredients. With its unique properties, such as small droplet size, nanoemulsion makes an attractive option for application in the pharmaceutical industry. It significantly improves the bioavailability of hydrophobic drugs, where its market is primarily driven by its stability and chemical properties, increasing the adoption of targeted therapies and minimally invasive procedures. The Nanoemulsion Market is Segmented by Application (Anesthetics, Antibiotics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Immunosuppressants, Steroids, and Other Applications), Route of Administration (Oral, Parenteral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for all the above segments.